NCT06986837Completed
Role of Inflammasome in Platelet Activation in Sickle Cell Disease Patient
Source: ClinicalTrials.gov · Last updated 23 May 2025
Brief summary (registry, in English)
Sickle cell disease is characterized by chronic hemolytic anemia, painful crisis called vaso-occlusive crisis and chronic inflammation. Activated platelets of Sickle cell disease patients participated to both chronic inflammation and painful vaso-occlusive crisis . The main aim of this study is to characterize the contribution of Nucleotide-binding domain Leucine Rich repeat containing Protein 3 inflammasome in platelets' activation in Sickle cell disease and to connect platelet activation, inflammation and sickle cell disease complication.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 92 (actual)
- First submitted
- 6 May 2025
- Start date
- 14 Oct 2020
- Primary completion date
- 5 Feb 2023
- Lead sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
- Diseases
- Sickle cell disease
- NCT number
- NCT06986837
What you commit to
- Study type: Observational
- Participants enrolled: 92
- From 14 Oct 2020 to the primary completion date, 5 Feb 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- \- patients with hemoglobinopathy other than SS and SC Sickle cell disease
- patients with a transfusion therapy or on bleeding therapy for less than three months
Other
- patients no affiliated to national social security
- pregnant or breastfeeding patients
- patients who will not provide written informed consent in accordance with the Declaration of Helsinki
Who the study is looking for
- patients with SS or SC Sickle cell disease
- diagnosis of SCD performed by electrophoresis or HPLC in a reference laboratory for hemoglobinopathies
- clinically in a steady state at inclusion (without complication in the last month and without transfusion in the three last months)
- patient followed up for Sickle cell disease at the sickle cell center of Guadeloupe (University hospital of Guadeloupe, Pointe à Pitre)
- patients who will provide written informed consent in accordance with the Declaration of Helsinki
- patients affiliated to national social security
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de la Guadeloupe Coordinator of this site? Confirm its status | Pointe-à-Pitre | Guadeloupe | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.